A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. (September 2017)

• Record Type: Journal Article
• Authors: Hardmeier, Martin; Leocani, Letizia; Fuhr, Peter
• Is Part Of: Multiple sclerosis. Volume 23:Number 10(2017)
• Page Start: 1309
• Page End: 1319
• Publication Date: 2017-09
• Subjects: Evoked potentials -- visual evoked potentials -- somatosensory evoked potentials -- motor evoked potentials -- multimodal evoked potentials -- electrophysiology -- biomarker -- remyelination -- phase-II trials; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458517707265
• Languages: English
• ISSNs: 1352-4585

Abstract

Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment.